• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

    15.32 +0.91 (+6.32%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,884,650
    Open 14.45
    Bid (Size) 15.12 (5,000)
    Ask (Size) 15.21 (100)
    Prev. Close 14.41
    Today's Range 14.11 - 15.50
    52wk Range 12.73 - 39.89
    Shares Outstanding 70,814,462
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    -35.1%
    -35.1%
    1 Month
    -39.2%
    -39.2%
    3 Month
    -50.1%
    -50.1%
    6 Month
    -20.6%
    -20.6%
    1 Year
    -49.5%
    -49.5%

    More News

    Read More
    News headline image
    Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
    From Pomerantz LLP
    Via GlobeNewswire
    Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise ↗
    Via Chartmill
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
    From Pomerantz LLP
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    Gapping stocks in Thursday's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy ↗
    Via MarketBeat
    News headline image
    Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx (RARE) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Ultragenyx Pharmaceutical Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
    From Calidi Biotherapeutics, Inc
    Via GlobeNewswire
    News headline image
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
    Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
    What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
    Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
    The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
    What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
    The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 15.32
    When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
    The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 09/29/26 04:00 PM ET
    What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
    The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.08B
    How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
    Ultragenyx Pharmaceutical Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.